Qol Holdings Co., Ltd.

3034.T·Tokyo·Healthcare
Compare
2,331.00−101.00 (−4.15%)today
At close: Oct 21, 3:30 PM JST · May be delayed up to 20 min · JPY

Prices may be delayed up to 20 min. Not investment advice. News volume: articles in the 4Search index each day.

Key statistics

Previous close2,432.00
Open2,440.00
Day range2,331.002,442.00
52-week range1,681.002,655.00
Off day high−4.55%
Off 52-week high−12.20%
Volume144.70K
Avg. volume (3M)146.22K
Market cap87.59B
EPS (TTM)254.57
Forward P/E7.12
P/E ratio (TTM)9.16
Dividend yield2.22% (54.00)
Beta (5Y)-0.02
Shares outstanding37.58M
Short interest—
Earnings dateJul 31, 2025 (est.)
Analyst target2,400.00
Profit margin2.92%

Against its peers

Compare in full ›
3034.T 6618.HK 0241.HK 3349.T 3148.T 002727.SZ
Market cap 87.59B 124.14B 47.47B 501.14B 205.44B 7.76B
P/E (TTM) 9.2 17.9 22.6 15.6 12.2 27.6
Forward P/E 7.1 13.2 15.9 17.3 — 14.4
Price/book 1.5 1.7 2.3 1.7 1.3 1.0
Dividend yield 2.22% — 2.25% 1.28% 2.99% 3.06%
1-year change +19.92% −35.65% −49.17% −11.43% +0.16% −6.50%
Today −4.15% −2.21% −3.77% −3.36% −1.09% +1.30%

The closest companies by business and industry (Pharmaceutical Retailers). Prices may be delayed up to 20 min.

Latest news

All 3034.T news ›
Medscape·Positive

Watchful Waiting Has Lasting QOL Benefit in Rectal Cancer

Patients who are able to undergo watchful waiting instead of immediate surgery for locally advanced rectal cancer can see lasting gains in quality of life (QOL), according to a new analysis of two clinical trials. Researchers found that of…

TCTMD.com·Positive

EVAR-First Strategy for Ruptured AAA Provides Early QoL Benefit.

Thirty-day results, published online January 13, 2014, in the BMJ, showed no difference in mortality or cost between the 2 approaches. No Mortality Difference per Protocol or per Treatment After 1 year, all-cause mortality rates were…

@onclive·

Dr Morgans on QOL With Darolutamide in mHSPC

Alicia Morgans, MD, MPH, discusses quality-of-life analyses from the ARANOTE and ARASENS trials in metastatic hormone-sensitive prostate cancer. Alicia Morgans, MD, MPH, discusses quality-of-life analyses from the ARANOTE and ARASENS…

From articles in the 4Search news index.

Market data is provided for information only and comes from free public sources. Prices may be delayed up to 15 minutes; data may be incomplete or inaccurate. Nothing on this page is investment advice or a recommendation to buy or sell any security. News and coverage analytics are drawn from the 4Search index. Terms of use.